OSE Pharma SA, an immuno-oncology company developing a T-specific immunotherapy for late-stage cancer patients, has taken further steps in its pharmaceutical development by successfully manufacturing its lead product Tedopi in compliance with good manufacturing practices (GMP) at a dedicated facility, certified both in Europe and the U.S. This announcement comes a few weeks after several European regulatory authorities issued a positive opinion so that OSE Pharma may initiate its pivotal phase 3...